Cellebrite DI (NASDAQ:CLBT) Upgraded to Buy at Wall Street Zen

Cellebrite DI (NASDAQ:CLBT) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

CLBT has been the subject of a number of other reports. Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday. JPMorgan Chase & Co. reduced their price target on Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, May 12th. Finally, Lake Street Capital reduced their price target on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $21.00.

Cellebrite DI Stock Up 2.0%

NASDAQ CLBT opened at $15.60 on Friday. The stock has a market cap of $3.74 billion, a PE ratio of -20.53, a P/E/G ratio of 3.09 and a beta of 1.27. The business has a 50 day moving average price of $14.98 and a two-hundred day moving average price of $17.82. Cellebrite DI has a fifty-two week low of $13.10 and a fifty-two week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. The business had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 25.28%. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 earnings per share. Sell-side analysts anticipate that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellebrite DI

Several large investors have recently modified their holdings of CLBT. Bosun Asset Management LLC lifted its holdings in Cellebrite DI by 1.4% during the 4th quarter. Bosun Asset Management LLC now owns 43,307 shares of the company’s stock worth $954,000 after buying an additional 584 shares during the last quarter. OneDigital Investment Advisors LLC lifted its holdings in Cellebrite DI by 2.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company’s stock worth $556,000 after buying an additional 688 shares during the last quarter. Signaturefd LLC lifted its holdings in Cellebrite DI by 68.3% during the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after buying an additional 819 shares during the last quarter. TD Waterhouse Canada Inc. lifted its stake in Cellebrite DI by 1.8% during the fourth quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company’s stock worth $1,046,000 after purchasing an additional 859 shares during the last quarter. Finally, SkyView Investment Advisors LLC lifted its stake in Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after purchasing an additional 970 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.